Log in

OTCMKTS:IGXT - IntelGenx Technologies Stock Price, Forecast & News

$0.55
+0.01 (+1.85 %)
(As of 12/8/2019 04:00 PM ET)
Today's Range
$0.53
Now: $0.55
$0.55
50-Day Range
$0.52
MA: $0.57
$0.68
52-Week Range
$0.39
Now: $0.55
$0.80
Volume43,750 shs
Average Volume61,210 shs
Market Capitalization$51.44 million
P/E RatioN/A
Dividend YieldN/A
Beta1.68
IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:IGXT
CUSIP45822R101
Phone514-331-7440

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.82 million
Book Value$0.11 per share

Profitability

Net Income$-10,110,000.00
Net Margins-792.90%

Miscellaneous

Employees38
Market Cap$51.44 million
Next Earnings Date3/27/2020 (Estimated)
OptionableNot Optionable

Receive IGXT News and Ratings via Email

Sign-up to receive the latest news and ratings for IGXT and its competitors with MarketBeat's FREE daily newsletter.


IntelGenx Technologies (OTCMKTS:IGXT) Frequently Asked Questions

What is IntelGenx Technologies' stock symbol?

IntelGenx Technologies trades on the OTCMKTS under the ticker symbol "IGXT."

How were IntelGenx Technologies' earnings last quarter?

IntelGenx Technologies Corp. (OTCMKTS:IGXT) announced its quarterly earnings data on Thursday, November, 7th. The company reported ($0.03) earnings per share for the quarter, meeting the consensus estimate of ($0.03). The firm had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.20 million. IntelGenx Technologies had a negative net margin of 792.90% and a negative return on equity of 162.47%. View IntelGenx Technologies' Earnings History.

When is IntelGenx Technologies' next earnings date?

IntelGenx Technologies is scheduled to release their next quarterly earnings announcement on Friday, March 27th 2020. View Earnings Estimates for IntelGenx Technologies.

What price target have analysts set for IGXT?

3 analysts have issued 1-year target prices for IntelGenx Technologies' shares. Their forecasts range from $1.00 to $1.60. On average, they expect IntelGenx Technologies' stock price to reach $1.37 in the next twelve months. This suggests a possible upside of 148.5% from the stock's current price. View Analyst Price Targets for IntelGenx Technologies.

What is the consensus analysts' recommendation for IntelGenx Technologies?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IntelGenx Technologies in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IntelGenx Technologies.

What are Wall Street analysts saying about IntelGenx Technologies stock?

Here are some recent quotes from research analysts about IntelGenx Technologies stock:
  • 1. According to Zacks Investment Research, "IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The Company's research and development pipeline includes products for the treatment of osteoarthritis pain management, hypertension and smoking cessation. " (12/4/2019)
  • 2. Maxim Group analysts commented, "IntelGenX reported 2Q19 revenue of $197k, a net loss of ($2.5M) and ended the period with $6.1M in cash on the balance sheet. At the current burn rate, the company should have runway into early 2020 though it’s likely the company needs to raise capital (assumed in our model)." (8/9/2019)
  • 3. HC Wainwright analysts commented, "We maintain our Buy rating of IGXT and maintain our 12-month price target of $1.50 per diluted share. We derive our price target based on the average of two valuation methods: 1) price-earnings multiple using 25x 2025 EPS estimate discounted at 15%; and 2) discounted cash flow analysis using a 2% terminal growth rate and discounting 2025 free cash flow estimate at a 15% discount rate. (1) partnership; (2) manufacturing; (3) commercial; (4) financial; and (5) intellectual property." (3/26/2019)

Has IntelGenx Technologies been receiving favorable news coverage?

Press coverage about IGXT stock has trended somewhat positive recently, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. IntelGenx Technologies earned a news impact score of 0.9 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for IntelGenx Technologies.

Who are some of IntelGenx Technologies' key competitors?

What other stocks do shareholders of IntelGenx Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IntelGenx Technologies investors own include Cronos Group (CRON), New Residential Investment (NRZ), Energy XXI Gulf Coast (EGC), Exelixis (EXEL), SandRidge Energy (SD), NovaBay Pharmaceuticals (NBY), Unilife (UNISQ), ACADIA Pharmaceuticals (ACAD), SemiLEDs (LEDS) and IntelGenx Technologies (IGX).

Who are IntelGenx Technologies' key executives?

IntelGenx Technologies' management team includes the folowing people:
  • Dr. Horst G. Zerbe, Founder, Chairman, CEO, Pres & Chairman of Scientific Advisory Board (Age 72)
  • Mr. Andre Godin C.A., CPA, CPA, CA, Exec. VP & CFO (Age 55)
  • Dr. Dana Matzen, VP of Bus. & Corp. Devel. (Age 41)
  • Ms. Nadine Paiement, Vice-Chair of Scientific Advisory Board and VP of R&D (Age 42)
  • Ms. Ingrid Zerbe, Co-Founder & Corp. Sec. (Age 65)

How do I buy shares of IntelGenx Technologies?

Shares of IGXT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is IntelGenx Technologies' stock price today?

One share of IGXT stock can currently be purchased for approximately $0.55.

How big of a company is IntelGenx Technologies?

IntelGenx Technologies has a market capitalization of $51.44 million and generates $1.82 million in revenue each year. The company earns $-10,110,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis. IntelGenx Technologies employs 38 workers across the globe.View Additional Information About IntelGenx Technologies.

What is IntelGenx Technologies' official website?

The official website for IntelGenx Technologies is http://www.intelgenx.com/.

How can I contact IntelGenx Technologies?

IntelGenx Technologies' mailing address is 6420 ABRAMS, VILLE SAINT LAURENT A8, H4S 1Y2. The company can be reached via phone at 514-331-7440 or via email at [email protected]


MarketBeat Community Rating for IntelGenx Technologies (OTCMKTS IGXT)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  142 (Vote Outperform)
Underperform Votes:  147 (Vote Underperform)
Total Votes:  289
MarketBeat's community ratings are surveys of what our community members think about IntelGenx Technologies and other stocks. Vote "Outperform" if you believe IGXT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IGXT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel